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ABSTRACT
Cholera toxin (CT), secreted from Vibrio cholerae, causes a massive fluid and electrolyte
efflux in the small intestine that results in life-threatening diarrhea and dehydration which
impacts 3-5 million people per year. CT is secreted into the intestinal lumen but acts within the
cytosol of intestinal epithelial cells. CT is an AB5 toxin that has a catalytic A1 subunit and a cell
binding B subunit. CT moves from the cell surface to the endoplasmic reticulum (ER) by
retrograde transport. Much of the toxin is transported to the lysosomes for degradation, but a
secondary pool of toxin is diverted to the Golgi apparatus and then to the ER. Here the A1
subunit detaches from the rest of the toxin and enters the cytosol. The disordered conformation
of free CTA1 facilitates toxin export to the cytosol by activating a quality control mechanism
known as ER-associated degradation. The return to a folded structure in the cytosol allows CTA1
to attain an active conformation for modification of its Gsα target through ADP-ribosylation.
This modification locks the protein in an active state which stimulates adenylate cyclase and
leads to elevated levels of cAMP. A chloride channel located in the apical enterocyte membrane
opens in response to signaling events induced by these elevated cAMP levels. The osmotic
movement of water into the intestinal lumen that results from the chloride efflux produces the
characteristic profuse watery diarrhea that is seen in intoxicated individuals.
The current model of intoxication proposes only one molecule of cytosolic toxin is
required to affect host cells, making therapeutic treatment nearly impossible. However, based on
emerging evidence, we hypothesize a threshold quantity of toxin must be present within the
cytosol of the target cell in order to elicit a cytopathic effect. Using the method of surface
plasmon resonance along with toxicity assays, I have, for the first time, directly measured the
efficiency of toxin delivery to the cytosol and correlated the levels of cytosolic toxin to toxin
iii

activity. I have shown CTA1 delivery from the cell surface to the cytosol is an inefficient process
with only 2.3 % of the surface bound CTA1 appearing in the cytosol after 2 hours of
intoxication. I have also determined and a cytosolic quantity of more than approximately .05ng
of cytosolic CTA1 must be reached in order to elicit a cytopathic effect. Furthermore, CTA1
must be continually delivered from the cell surface to the cytosol in order to overcome the
constant proteasome-mediated clearance of cytosolic toxin. When toxin delivery to the cytosol
was blocked, this allowed the host cell to de-activate Gs, lower cAMP levels, and recover from
intoxication. Our work thus indicates it is possible to treat cholera even after the onset of disease.
These findings challenge the idea of irreversible cellular toxicity and open the possibility of postintoxication treatment options.
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CHAPTER ONE: INTRODUCTION
Vibrio cholerae
Vibrio cholerae is a Gram negative, waterborne pathogen transmitted through a fecal-oral
route. Infection occurs from ingesting food or water contaminated with the bacterium which
subsequently colonizes the small intestine and releases a toxin. The resulting disease affects 3-5
million people and causes 100,000–120,000 deaths per year [1]. Although cases have been rare
in industrialized nations, it is still prevalent in various areas with inadequate sanitation measures.
WHO reports recent outbreaks of cholera in Haiti, Pakistan, and Central Africa and highlight the
ever present presence of this disease worldwide. Infected individuals exhibit massive fluid and
electrolyte efflux in the small intestine that results in life-threatening diarrhea and dehydration.
One in twenty infected individuals has a severe reaction and can exhibit profuse watery diarrhea,
losing up to 6 liters of fluid per day. Without proper treatment, dehydration and shock resulting
in death can occur within hours [2]. Current treatment for the deadly symptoms of this disease
included rehydration in the form of an oral rehydration salt solution or, in more serious cases,
administration of intravenous Ringer's lactate [3]. Recovery from cholera occurs after the
intoxicated enterocytes, which have a 3-5 day life span [4], are sloughed from the intestinal
epithelium. Antibiotics aimed to kill the bacteria are effective but seldom available in affected
areas, and emerging antimicrobial resistance to various strains is of concern [5]. As the disease
results from a toxin secreted by V. cholerae, the toxin directly could be a potential target for
therapeutic development.

Cholera Toxin
Cholera toxin (CT), secreted from V. cholerae, causes a massive fluid and electrolyte

1

efflux in the small intestine that results in life-threatening diarrhea and dehydration. V.choerae
colonizes the lining of the small intestine and begins to produce CT once it has safely passed the
acidic pH of the stomach. CT is the main virulence factor of V. choerae and is released from the
bacterium into the extracellular environment [6].CT in the medium must bind to and enter the
host cell in order reach its Gsα target within the cytosol of the cell. In order to reach the cytosol,
translocation from the endoplasmic reticulum (ER) is required. This occurs after CT has been
transported in a retrograde manner from the cell surface to this location [7].
CT is an AB5 toxin which has a catalytic A1 subunit and a homopentameric cell binding
B subunit. The A chain is proteolytically nicked to produce a disulfide-linked A1/A2
heterodimer. The A2 subunit and B pentamer also maintain non-covalent interactions with
CTA1 which secure the A1 subunit to the rest of the toxin [8].

Retrograde Transport
Retrograde transport is a normal cellular process that moves cargo from the plasma
membrane to the ER with the aid of vesicle carriers. CT uses this retrograde transport to move
from the cell surface to the ER on the path to its target in the cytosol. CT, due to its lack of pore
forming ability, must utilize channels in the ER to move into the cytosol. The toxin first binds to
the GM1 ganglioside receptors on the surface of intestinal epithelial cells and is subsequently
internalized by a clathrin-independent pathway. The toxin is directed to the early endosomes,
with a majority of internalized toxin transported to the lysosomes for degradation. A lesser
amount moves to the Golgi apparatus and then to the ER. The resident redox state of the ER
leads to reduction of the CTA1/CTA2 disulfide bond. As determined by reduction of the
CTA1/CTA2 disulfide bond which occurs in the ER, only 3-10% of surface bound toxin reaches
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the ER after 1-2 hours of exposure [9-12]. Dissociation of reduced CTA1 from CTA2/CTB5 does
not occur spontaneously but requires the aid of chaperones. Once freed from the rest of the toxin,
the CTA1 polypeptide can pass through an ER translocation pore to the cytosol. The efficiency
of this delivery to the cytosol has never been determined.

Toxin Translocation from the ER to the Cytosol
The isolated CTA1 subunit is a disordered, thermally unstable protein. It assumes a
disordered conformation after separation from the holotoxin in the ER, and regains an ordered
conformation after entry into the cytosol. The disordered tertiary conformation of free CTA1
facilitates toxin export to the cytosol by activating a quality control mechanism known as ERassociated degradation (ERAD). This pathway is generally used to expel misfolded or
misassembled secretory proteins from the ER for degradation in the cytosol. Unfolded CTA1
mimicks an unfolded substrate and is able to thus reach the cytosol using ERAD to move through
a protein-conducting channel in the ER membrane. Terminally misfolded proteins are targeted to a
translocon by a complex of chaperones [13].

Drugs with known functions such as sodium 4-phenylbutyrate (PBA), glycerol, and
geldanamycin (GA) have been used to block defined steps in the CTA1 intoxication [4,14,33].
PBA and glycerol both block the unfolding of dissociated CTA1 to a translocation competent
state and thus prevent CTA1 export from the ER to the cytosol, while GA prevents the chaperone
mediated refolding of CTA1 once in the cytosol. Since PBA is an FDA-approved drug for the
treatment of urea cycle disorders and GA is being used in clinical trials as an anti-cancer agent,
they could possibly be used to treat cholera [14].
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Toxin Extraction from the ER by Hsp90
Unfolded or misfolded ERAD substrates are exported out of the ER via proteinconducting channels [16-17]. Host cytosolic factors must produce the driving force for substrate
extraction from these ER-specific channels. ERAD processing involves multiple host
chaperones, proteins that assist in protein folding and/or unfolding and the assembly or
disassembly of macromolecular structures. These chaperones prevent the aggregation of
misfolded proteins in the ER and can direct ERAD substrates to the proteasome for degradation.
In the case of CTA1, chaperones assist the refolding of CTA1 into an active conformation once it
has entered the cytosol. Chaperones are required to stabilize and/or refold the toxin because its
thermal instability at physiological temperature leaves it in a disordered state. Most ERAD
substrates are extracted from the ER through a pathway that involves p97 [18]. However, p97 has
been determined not to play any role in CTA1 dislocation [19,20].The cytosolic chaperone Hsp90

helps extraction from the ER [21] and it has been shown that it is required for CTA1 passage into
the cytosol. Hsp90 bound to CTA1 in an ATP-dependent manner was blocked by geldanamycin
(GA), an established Hsp90 inhibitor. GA has been shown to inhibit the chaperone Hsp90mediated refolding of CTA1 in the ER as well as block intoxication in cultured cells and fluid
accumulation when used in rabbit ileal loop studies. GA is currently in clinical trials as an anticancer agent. GA thus represents a promising therapeutic for the treatment of cholera.

Toxin Degradation in the Cytosol
The cell itself has a multitude of mechanisms, such as the previously mentioned
lysosome, to reduce the level of waste proteins. Within the cytosol, the proteasome is in place to
reduce the level of misfolded proteins. After export to the cytosol, ERAD substrates are
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ubiquitinated to target them for degradation by the 26S proteasome [15-16, 22-23]. The
proteasome is a cylindrical complex containing central barrel shaped pore known as the 20S
“core” and two 19S "cap" that recognizes the polyubiquitin tags and initiates the degradation
process with ATP-depending unfolding [24]. CTA1 avoids degradation by the 26S proteasome
because it contains only two lysine residues that are normally the sites of ubiquitin conjugation
[25]. However, when CTA1 is unfolded it is susceptible to ubiquitin-independent degradation by
the 20S proteasome. This variant of the proteasome consists of only the catalytic core of the 26S
proteasome, thus lacking the ubiquitin recognition and ATP-dependent activities of the 19S cap
seen in the 26S proteasome [26]. The Teter lab has further shown that the cytosolic pool of
CTA1 is degraded by this mechanism with a half-life of 2 hours, and the use of proteasome
inhibitors increased this time. These results suggest the amount of cytosolic toxin is proportional
to the amount of toxicity.

Toxin Activity in the Cytosol
Once in the cytosol, CTA1 attains an active refolded conformation with the aid of
chaperones such as Hsp90. Refolded CTA1 activates the stimulatory  subunit of the
heterotrimeric G protein which is located in lipid rafts at the cytoplasmic face of the eukaryotic
plasma membrane [27]. CTA1 modifies its Gsα target by ADP-ribosylation. Gsα is a molecular
switch that is regulated by GTP binding and hydrolysis. Catalytically active CTA1 fixes Arg201
of Gs with ADP-ribose which prevents its ability to hydrolyze bound GTP and thus locks it in
an active state. This results in overstimulation of adenylate cyclase, causing an increase in the
production of the secondary messenger cAMP above normal levels. If CT intoxication is not
halted, the subsequent dysregulation of cAMP levels leads to the opening of the cystic fibrosis
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transmembrane conductance regulator (CFTR) channel in the apical plasma membrane of the
intestinal epithelial cell. This, in turn, stimulates chloride secretion and ultimately leads to an
efflux of water into the lumen of the small intestine [28]. The osmotic movement of water
produces a diuretic response which is responsible for the rapid and extreme dehydration that is
seen in intoxicated individuals.

Reversal of Toxin Activity
In addition to the ability to degrade CTA1 directly, the cell has mechanisms in place to
reverse the toxin-activated signaling pathway. The host cell has a multitude of mechanisms in
place to regulate and degrade common cytosolic events and components. The host ADPribosyl(arginine)protein hydrolase will catalyze the removal of the ADP-ribose moiety from the
locked, active G protein [29]. This will allow Gsα to turn off by hydrolyzing its bound GTP.
There is also a rapid turnover of ADP-ribosylated Gsα by the proteasome [30]. This substantially
reduces the amount of ADP-ribosylated Gsα in the cell. Phosphodiesterases are able to degrade
cAMP and can reduce concentrations back to basal level. With these mechanisms in place, we
hypothesize CTA1 must be continually delivered to the cytosol in order to overcome the constant
cellular pressures which degrade CTA1 and reverse its activity. This is contrary to the current
paradigm, described below, that only one molecule of cytosolic toxin is required to irreversibly
affect host cells [31-32]. The cell’s ability to degrade CTA1 and reverse toxin activity is
indicative of the requirement of more than one molecule for intoxication and consistent with
results that show levels of cytosolic toxin proportional to the level of toxicity. Current
treatments do not sufficiently block translocation of CTA1 to the cytosol and the fight between
entry and degradation favors toxicity over reversal by the cell. New therapeutics that may more
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efficiently block translocation may be able to lower the quantity of toxin to a level at which the
balance may favor the cell’s innate mechanisms. Thus, it is theoretically possible to reverse
effects of cholera intoxication.

Current Model
It is widely thought that AB toxins such as CT are essentially so potent that it only takes
one to a few molecules of cytosolic toxin to generate a toxic effect. Furthermore, the cellular
effects of CT are still considered irreversible. Thus, the dominant model views the diarrhea from
cholera as an irreversible event. It is thought that individuals only recover from cholera when
the intoxicated cells are sloughed from the epithelial monolayer. This model of intoxication
implies the idea of a post-intoxication therapeutic treatment is nearly impossible.

Hypothesis
We hypothesize a threshold quantity of toxin must be present within the cytosol of the
target cell in order to elicit a cytopathic effect. Our model contradicts the currently accepted
theory that one molecule of toxin is enough to induce toxicity in the cell. Previous studies
provided only indirect measures of cytosolic toxin with a high level of error and did not address
the relationship between toxin quantity and toxin activity within the cytosol [39-40]. With recent
advances in technology, we can now detect cytosolic CTA1 using surface plasmon resonance
(SPR) [4,14,33-35]. This SPR assay is an innovative way to look at precise CTA1 cellular
content at levels too low to be previously detected. This assay will allow us to draw correlations
between the levels of cytosolic CTA1 to the extent of intoxication and could change the
paradigm of how we view the intoxication process. Using this method we have been able to
measure the efficiency of toxin delivery to the cytosol and correlated the levels of cytosolic toxin
7

to toxin activity. I have shown only 2.3 % of the surface bound CTA1 appeared in the cytosol
after 2 hours of intoxication. I have also determined and a cytosolic quantity of more than .05ng
of cytosolic CTA1 must be reached and maintained in order to elicit a cytopathic effect and
overcome the constant proteasome-mediated clearance of cytosolic toxin. Blocking toxin
trafficking allowed the host cell to de-activate Gs, lower cAMP levels, and recover from
intoxication. Our work thus indicates it is possible to treat cholera even after the onset of disease
and challenges the idea of irreversible cellular toxicity while opening the possibility of postintoxication treatment options.
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CHAPTER TWO: METHODOLOGY
Chemicals and Reagents
Sigma Aldrich (St. Louis, MO)


Ethylenediaminetetraacetic Acid (EDTA)



Protease Inhibitor Cocktail



Tetramethylethylenediamine (TEMED)



Monosialoganglioside GM1 from bovine brain,



3-Isobutyl-1-Methylxanthine (IBMX)



Digitonin



Brefeldin A



ALLN



Glycerol

Fisher Scientific (Pittsburgh, PA)


2-Mercaptoethanol (β-ME)



Ethanol 200 proof (EtOH)



Gel Code Blue Stain Reagent



Glycerol



Methanol (MeOH)



Sodium Chloride (NaCl)



Sodium Hydroxide (NaOH)



Sodium Phosphate Dibasic Anhydrous (Na2HPO4)
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Sodium Phosphate Dibasic Heptahydrate (Na2HPO4·7H2O)



Sodium Phosphate Monobasic Anhydrous (NaH2PO4) Sodium



Phospate Monobasic Monohydrate (NaH2PO4·H2O) Tris Base



Tryptone



Tween-20

Stressgen (Farmingdale, NY)


Geldanamycin

Invitrogen (Carlsbad, CA)


Antibiotic-Antimycotic



Dulbecco’s Modified Eagle Medium (DMEM)



Ham’s F-12



Trypsin/EDTA

Amresco (Solon, OH)


Ammonium Persulfate (APS)



Bromophenol Blue



Glycine



HEPES



Methionine



Sodium Dodecyl Sulfate (SDS)



Tris-Cl



Triton X-100
10

Calbiochem (La Jolla, CA)


Digitonin



Sodium 4-phenylbutyrate (PBA)

Bio Rad (Hercules, CA)


40% Acrylamide /Bis Solution



Extra Thick Filter Paper

Atlanta Biologicals (Lawrenceville, GA)


Fetal Bovine Serum

Pierce Biotechnology, Inc (Rockford, IL)


N-hydroxysuccinimide (NHS)

Thermo Scientific (Waltham, MA)


1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC)

Gibco (Grand Island, NY)


DMEM



Antibiotic-Antimycotic

GE Healthcare (Piscataway, NJ)


ELISA cAMP kit



Western blotting detection reagents
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Toxins
List Biological Laboratories (Campbell, CA)


Cholera Toxin, Holotoxin

Calbiochem (La Jolla, CA)


Cholera Toxin, A subunit

Antibodies
Stressgen (Ann Arbor, MI)


Rabbit α-Hsp90



Rabbit α-PDI

Sigma Aldrich (St. Louis, MO)


Rabbit α-CTA

Jackson Immunoresearch (West Grove, PA)


Goat anti-Rabbit IgG conjugated to HRP

Equipment
Bio Rad (Hercules, CA)


Bio Rad Power Pac Basic



Bio Rad Power Pac HC



Trans-Blot SD Semi-Dry Transfer Cell
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BioTek Instruments (Winooski, VT)


Synergy 2 Plate Reader

Other Materials
Grenier Bio One


6-well flat-bottom tissue culture plates



24-well flat-bottom tissue culture plates

American Type Culture Collection


Chinese Hamster Ovary (CHO) cells



HeLa cells

Buffers
Phosphate Buffered Saline (PBS), 10x


82.3 g Na2HPO4 (0.58M)



23.5 g NaH2PO4 (0.17M)



40 g NaCl (0.69M)



H2O to 1 liter

Tris-Buffered Saline (TBS)


10x 24.24 g Tris-Cl



5.56 g Tris Base



80.1 g NaCl



H2O to 1 liter
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Transfer Buffer


100 ml 10x SDS-Electrophoresis Running Buffer



200 ml MeOH



600 ml H2O

SDS-Electrophoresis Running Buffer, 10x


30.2 g Tris Base



144 g Glycine



10 g SDS H2O to 1 liter

SDS Sample Buffer, 4x


50 ml 4x Tris-Cl/SDS pH 6.8



40 ml Glycerol



8 g SDS



2 mg bromophenol blue



100 mM 2-mercaptoethanol (7µl of 14.3 M ß-ME /ml of 4x buffer)

HCN Buffer


50 mM HEPES, pH 7.5



150 mM NaCl



2 mM CaCl2



10 mM N-ethyl maleimide (NEM)



1:20 dilution of Protease Inhibitor Cocktail
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Cell Culture
HeLa cells were grown in DMEM media supplemented with 10% fetal bovine serum
(FBS) and 1% antibiotic-antimycotic at 37°C and 5% CO2 unless otherwise indicated.

Detection of Cytosolic CTA1
HeLa cells were seeded in triplicate to 6-well plates in complete DMEM medium to
achieve an 80% confluent monolayer after an overnight incubation. Cells were incubated in
serum free DMEM containing 100 ng/mL of ganglioside GM1 for 1 h at 37°C. GM1 receptor is
added to the medium because HeLa cells do not normally express this receptor but will
incorporate it from the medium into the plasma membrane. After washing with phosphate
buffered saline (PBS) to remove excess GM1, the cells were subsequently incubated for 30 min
at 4°C with DMEM containing 1 µg/ml of CT. After this incubation, the cells were washed twice
with PBS to remove unbound CT. At this point, surface bound CT can be determined via
digitonin permeabilization and SPR analysis (as described below) of the pellet fraction
containing surface bound CT. The washed cells were placed in toxin-free/serum-free media and
returned to 37°C for various time points and treatments as indicated. Only when the plates are
moved to the 37°C incubator is the toxin internalized; at this stage the chase interval begins.
After washing with PBS at the end of each chase point, digitonin permeabilization was
performed to separate cytosolic and outermembrane fractions to be used to analyze the cytosolic
content of CTA1 by SPR. This process was begun at the end of each chase interval as well as at
the end of the 4°C pulse labeling by lifting cells from the 6-well plate using a 5 minute 4°C
incubation with 400 µl of 0.5 mM ethylenediaminetetraacetic acid (EDTA) in PBS. Triplicate
wells were collected into a single microcentrifuge tube and spun at 5,000× g for 5 min. The
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supernatant was discarded and the cell pellet was incubated on ice for 10 minutes. The cell pellet
was subsequently resuspended in 100 μl of 0.04% digitonin in HCN buffer (50 mM HEPES, pH
7.5, 150 mM NaCl, 2 mM CaCl2, 10 mM N-ethylmaleimide, and a protease inhibitor cocktail)
for 10 minutes at again on ice. The digitonin-permeabilized cells were then spun at 16,000 × g
for 10 min at room temperature, after which the supernatant (i.e., cytosolic fraction) was
collected and placed in a fresh microcentrifuge tube for SPR analysis. The membrane pellet was
collected from the pulse sample to determine total CTA1. Well specific cell counts were
recorded for each experiment with the use of a hemocytometer.

SPR Analysis
Experiments were performed with a Reichert (Depew, NY) SR7000 surface plasmon
resonance (SPR) refractometer. The flow rate for all steps was 41 μl/min. For experiments
involving antibody-coated plates, an EDC-NHS activation buffer with 0.08 mg/ml of 1-ethyl-3[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and 0.02 mg/ml of Nhydroxysuccinimide (NHS) mixed in a 1:1 ratio was perfused over a Reichert gold-plated glass
slide for 5 min. A 5 min wash with 10 mM PBS containing 0.05% Tween 20 (PBST) pH 7.4 was
used to remove the activation buffer, after which an monoclonal anti-CTA1 antibody at 1:2000
dilution in 20 mM sodium acetate, (pH 5.2) was perfused over the slide for 5 min. Unbound
antibody was removed with a 5 min PBST wash, and the remaining active groups on the sensor
slide were deactivated with a 5 min exposure to 1 M ethanolamine (pH 8.5). PBST was perfused
over the slide for 5 to 10 min to establish a stable baseline signal corresponding to the mass of
the sensor-bound antibody. Supernatant samples from the digitonin-permeabilized cells were
brought to a final volume of 1 ml in PBST pH 7.4, and pellet samples were brought to final
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volume of 1ml in PBST containing 1% Triton X-100. These samples were then perfused over the
sensor slide coated with an anti-CTA1 antibody. To establish a standard curve CTA standards
were diluted in PBST pH 7.4 to appropriate concentrations (500, 100, 10, 1, 0.1, 0.01, 0.001
ng/ml) and flowed over the CTA1 sensor slide for 5 min each, followed by a 5-min PBST wash.
The association rate constants for the CTA standards were plotted as a function of protein
concentration, and the slope of the resulting standard curve was then used to calculate the
quantity of CTA1 in experimental samples. Reichert LabView software was used for data
collection. The BioLogic (Campbell, Australia) Scrubber 2 software and WaveMetrics (Lake
Oswego, OR) Igor Pro software were used to analyze the data and generate figures. Binding
affinities between CTA1 and the antibody bound plate were calculated in the Scrubber 2
software.

Western Blot
For Western blot analysis, pellet and supernatant fractions were produced for digitoninpermeabilized as described above. 120 µl of 1× sample buffer was added to the pellet and 20 µl
of 4× sample buffer was added to the supernatant. Equivalent 25 ul volumes of each sample were
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 15%
polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membrane. The rabbit
anti-Hsp90 antibody was used at a 1:5,000 dilution and the rabbit anti-PDI antibody was used at
a 1:5,000 dilution for an overnight incubation at 4°C. The secondary horseradish peroxidaseconjugated goat anti-rabbit IgG antibody was used at a 1:20,000 dilution for a 30 minute room
temperature incubation. ECL Plus Western blotting detection reagents were used for protein
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detection according to the manufacturer's instructions. A blot was run to detect the presence of
the previously mentioned target proteins.

Toxicity Assay
HeLa cells as described in the above CT detection assay were also seeded and treated in
parallel to SPR and were used to detect cytotoxicity as values of cAMP. 6-well plates were
incubated overnight until 80% confluent. Cells were pretreated with GM1 and exposed to CT as
described above. At the end of the chase interval, the cells were washed with PBS and incubated
with 0.5 ml of ice-cold HCl-ethanol (1:100) for 15 min at 4°C. Supernatants were placed in
microcentrifuge tubes and allowed to air dry. cAMP levels were then determined using an
ELISA cAMP competition assay kit as per manufacturer instructions. The basal level of cAMP
from equivalent numbers of unintoxicated cells was also determined. All conditions were
performed in triplicate.

Calculation of Cytosolic CTA1 Levels
To calculate the precise amount of cytosolic CTA1 observed in the cell, CTA standards
were perfused over each SPR plate used to detect cytosolic CTA1. Using the Ka values from
these standards in comparison to the Ka values from out experimental samples, we could backcalculate the amount of CTA1 within the cytosol. With the use of a hemocytometer, cells counts
from each corresponding experiment were carried out and used to determine the amount of
CTA1 per cell.
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CHAPTER THREE: RESULTS
To determine the efficiency of CTA1 transport to the cytosol, we used digitonin
permeabilization to collect and SPR to quantify the amount of CTA1 in the cytosol.
HeLa cells treated with GM1 were exposed to toxin 1 µg/ml of CT at 4°C.Toxin can bind
to the cell surface at 4°C but is not endocytosed. At this point, the total cell-associated amount of
CT can be determined via digitonin permeabilization and SPR analysis of the pellet fraction
containing surface bound CT. For quantification of cytosolic CTA1, cells placed at 37°C for
various time points with or without drug treatments. Only when the plates are moved to the 37°C
incubator is the toxin internalized; at this stage the chase interval begins. After each chase point,
digitonin permeabilization was performed to separate cytosolic and membrane fractions to be
used to analyze the cytosolic content of CTA1 by SPR. 0.5 mM ethylenediaminetetraacetic acid
(EDTA) in PBS was used to collect cells from the plate. The cell pellet was subsequently
resuspended in 100 μl of 0.04% digitonin in HCN buffer for 10 minutes on ice. The digitoninpermeabilized cells were then spun at after which the supernatant (i.e., cytosolic fraction) was
collected and placed in a fresh microcentrifuge tube for SPR analysis. PBS was used to bring the
final volume of each cytosolic fraction to 1ml. Cell counts were recorded for each experiment
with the use of a hemocytometer.
To verify proper digitonin permeabilization generated clean cytosolic and organelle
fractions, both supernatant and pellet fractions collected from HeLa cells were run on SDSPAGE gels. Western blots against known cytosolic (Hsp90) and ER lumen (PDI) proteins were
used to confirm the reliability of the fractionation process by determining the distribution of
these proteins. Due to their known localization, Hsp90 should only be detected within the
supernatant fraction and PDI within the pellet fraction if fractionation was successful.
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Supernatant and pellet fractions from two independent experiments were used to demonstrate
reproducibility. Anti-Hsp90 and anti-PDI blots each detected only a single band at the
corresponding molecular mass and in the respective supernatant and pellet fraction indicating
accurate fractionation.
SPR can be used to detect protein-protein interactions as well as test for the presence of a
particular protein within a sample. For these experiments, a protein of interest is perfused in
microliter quantities over a gold and glass sensor slide that is coated with either a second protein
of interest or an antibody to the first protein. An interaction between the two proteins increases
the mass on the sensor slide, and this generates a change in the angle of reflected light which is
recorded as a refractive index unit (RIU) [35].
Cytosolic fractions from intoxicated cells were run over an anti-CTA1 SPR slide as
described previously. The cytosolic fractions from unintoxicated and 5ug/ml BFA-treated cells
were used as negative controls to ensure the fractionation procedure did not rupture the collected
organelles. BFA causes deregulation of membrane traffic through disassembly of the Golgi
complex and thus prevents toxin delivery to the ER translocation site. If contamination was
present, CTA1 would be detected in the cytosolic fraction of the unintoxicated or BFA treated
cells. However, Figure 2 shows no detection of CTA1 in these control cells. There is also no
detectable CTA1 within the cytosol of intoxicated cells after 15 minutes of toxin treatment
indicating that delivery from the cell surface to the cytosol takes a greater period of time to
occur. CTA1 was clearly seen within the cytosol after a 30 minute intoxication, with increasing
amounts of toxin appearing in the cytosol at later 60 and 120 minute chase intervals. CTA1
standards were also perfused over the anti-CTA1 SPR slide. The Ka values determined for these
standards were then plotted as a function of protein concentration (Fig 3). The slope of the
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resulting standard curve was then used to calculate the quantity of CTA1 in experimental
samples in Table 1. It was determined that after 30, 60 and 120 minutes .07ng, .12ng and .65ng
of CTA1 is present within the cytosol respectively. Furthermore, hemacytometer counts for each
experiment documented the number of collected cells and allowed us to determine the average
number of CTA1 molecules inside the cytoplasm of an individual cell. This was determined to be
9450, 16136, and 87832 molecules after 30, 60, and 120 minutes of chase respectively. This was
then compared to the amount of surface bound-CT at the beginning of the experiment and is
presented as a percentage of the initial cell-associated toxin and determined to be .25%, .43%
and 2.3% respectively. This work represents both the first direct calculation of toxin levels in the
cytosol of a host cell as well as the first calculation of efficiency of transport to the cytosol where
the toxin is active.
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Figure 1. Proper collection of membrane and cytosolic bound fractions

22

Figure 2. CTA1 is detected within the cytosol at after 30 minutes.
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Figure 3. Ka’s plotted as a function of protein concentration can be used to determine cytosolic
CTA1 quantities.
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Table 1. Efficiency of toxin delivery to the cytosol
Chase condition

ng cytosolic CTA1

CTA1 molecules per cell

% surface-associated CTA1

30 min

0.07 ± 0.03

9,454

0.25%

60 min

0.12 ± 0.06

16,137

0.43%

120 min

0.65 ± 0.16

87,832

2.3%
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The next step was to correlate the level of toxin in the cytosol with toxin activity by
examining intracellular cAMP levels in a time-dependent manner. Pulse-chase experiments were
carried out as described in the aforementioned translocation assay. Pulse sample with no chase
were used to determine background resting levels of cAMP activity. Intoxicated cells were
treated with acidic ethanol to lyse the cells. cAMP levels were then determined using an ELISA
cAMP competition assay kit as per manufacturer instructions (Figure 4). Cells were exposed to
CT in the absence (circles) or presence (squares) of 3-isobutyl-1-methylxanthine (IBMX), a
cAMP phosphodiesterase inhibitor that prevents the degradation of cAMP. IBMX- treated cell
had greater levels of cAMP then untreated cells at 60 and 120 minutes of chase, although there
was still no response above background at 30 minutes for either untreated or IBMX- treated
cells. This indicated those host cAMP phosphodiesterases can partially limit the cytopathic effect
of CT. Results shown in Figure 4 demonstrate a cAMP response is not present at the 30 minute
chase even though toxin is seen in the cytosol at 30 minutes (Fig 2, Table 1). This result suggests
the amount of toxin in the cytosol at 30 minutes of chase was not sufficient for a cAMP
response. We see here the suggestion of a threshold quantity of cytosolic CTA1 may be required
to elicit a toxic effect.
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Figure 4. Toxin activity lags behind toxin appearance in the cytosol
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This delay between CTA1 appearance in the cytosol and CTA1 activity in the cytosol
could reflect a kinetic requirement for cytosolic CTA1 to reach and activate its Gsα target. To
examine this possibility, we repeated our pulse-chase translocation assay with drug-treated cells.
.1uM GA and .1mM PBA were used to restrict CTA1 access to the cytosol by disrupting the ERto-cytosol export of CTA1. GA inhibits the Hsp90-driven extraction of CTA1 from the ER,
while PBA prevents the unfolding of CTA1 to a translocation-competent state, while neither
drug inhibits toxin transport to the ER. Figure 5 and 6 show PBA and GA treatment are sufficient
to inhibit toxin entry to the cytosol after 60 and 120 minutes respectively. Both GA and PBA are
in parallel able to reduce cAMP levels in intoxicated cells even after 60 and greatly after 120
minutes. PBA and GA were then used in combination and indicate co-treatment also inhibits
toxin entry to the cytosol in Figure 8. The addition of a 100uM ALLN, a known proteasome
inhibitor, was then used to determine the proteasomes role in intoxication. ALLN increases
CTA1 presence in the cytosol and thus plays a role in clearing the toxin from the cytosol. A
combination of GA and PBA reduces cAMP levels while the addition of a proteasome inhibitor
increases this level in intoxicated cells in Figure 9. The differing quantities and resulting cAMP
activity are then used to hone in on the threshold quantity of toxin required to elicit cytopathic
activity in the cell. Using these quantities and activity levels it is approximated that quantities
above .05 ± .02 ng would be sufficient to induce cytopathic activity.
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Table 2. A threshold quantity of cytosolic CTA1 is required to generate a cAMP response.
Chase condition

ng cytosolic CTA1

CTA1 molecules per cell

cAMP response

No treatment

0.25 ± 0.18

26,390

+

+ GA

0.03 ± 0.01

3,673

-

+ PBA

0.07 ± 0.02

7,652

-

No treatment

0.63 ± 0.32

66,577

+

+ ALLN

0.38 ± 0.06

40,198

+

+ GA

0.02 ± 0.01

2,032

-

+ PBA

0.04 ± 0.01

4,423

-

+ GA/PBA

0.02 ± 0.01

2,043

-

+ GA/PBA & ALLN

0.05 ± 0.02

5,655

+

60 min

120 min
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Figure 5. PBA and GA treatment are sufficient to inhibit toxin entry to the cytosol after 60
minutes.
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Figure 6. PBA and GA treatment greatly inhibit toxin entry to the cytosol after 120 minutes.
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Figure 7. Both GA and PBA reduce cAMP levels in intoxicated cells after 60 and 120 minutes.
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Figure 8. PBA/GA treatment inhibits toxin entry to the cytosol while the addition of a
proteasome inhibitor increases its presence.
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Figure 9. A combination of GA and PBA reduces cAMP levels while the addition of a
proteasome inhibitor increases this level in intoxicated cells.
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Figure 4 demonstrated that cAMP phosphodiesterases could limit the cAMP response to
CT. We examined whether host proteasome function could also limit the cAMP response to CT.
After 30 minutes of chase in our pulse-chase translocation assay, we prevented additional CTA1
from reaching the cytosol using 10% glycerol (Figure 10). This chemical chaperone prevents the
unfolding and ER-to-cytosol translocation of CTA1. Using this approach, we were able to
control toxin translocation. We labeled the cell surface with CT and allowed trafficking from the
cell surface through the cell for 30 minutes before adding glycerol. Again, ALLN, a proteasome
inhibitor, was added to a subset of glycerol-treated cells to examine the proteasome’s potential
role in toxin clearance from the cytosol. The amount of cytosolic toxin in untreated cells was
determined after 30 and 120 minutes. The amount of cytosolic toxin in glycerol-or
glycerol/ALLN- treated cells was determined after 120 minutes (drugs were applied 30 minutes
into chase). Unintoxicated cells and BFA-treated cells were used as negative controls. The
increase in cytosolic toxin from 30 to 120 minutes is comparable to what we have seen in that
there is an increasing accumulation of CTA1 in the cytosol over time. Treatment with glycerol
showed lower amounts of cytosolic toxin from 30 to 120 minutes in comparison to the untreated
sample at 120 minutes. This difference was due to the block of CTA1 entry to the cytosol. If this
glycerol induced block was the only factor contributing to toxicity the cytosolic quantity of toxin
would be steady and equivalent to that seen at 30 minutes, but we observe a loss of signal with
glycerol treatment. The loss of signal in these samples is due to toxin clearance by the
proteasome. This observation is validated by the use of ALLN along with glycerol treatment.
Glycerol- and ALLN-treated samples contained more cytosolic CTA1 than cells exposed to
glycerol alone which indicated clearance of cytosolic toxin from glycerol-treated cells was due to
proteasomal degradation. This again demonstrated proteasomal degradation has the ability to
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limit the accumulation of cytosolic toxin. Proteasomal activity can lower the quantity of CTA1
when translocation to the cytosol is blocked after exposure. Overall, this suggests that CTA1
must be continuously delivered to the cytosol to overcome proteasomal degradation.
Next, we again used toxicity assays to directly correlate the level of cytosolic toxin to the
extent of intoxication at 120 minutes. Figure 7 shows cells treated with glycerol treatment at 30
minutes after toxin exposure produced a cAMP response at 120 minutes chase that was barely
above the basal cAMP level from unintoxicated cells. This non-response corresponded to .01 ng
CTA1 present in the cytosol (Table 3). A greater quantity of .06 ng of cytosolic toxin was
obtained from cells exposed to both glycerol and ALLN, which resulted in a strong cAMP
response and is constant with the results seen with the cellular quantity derived from the previous
data (Figure 11). However, less CTA1 was in the cytosol of glycerol/ALLN-treated cells at 120
minutes of total chase than was present in the cytosol of untreated cells at 30 minutes postintoxication (Table 3). The lack of cAMP response after 30 minutes of chase thus indicated
there is a kinetic barrier, as well as a threshold requirement, for productive intoxication.
The need to reach a threshold quantity of cytosolic toxin for a cAMP response implied
that intoxication could be reversed if the level of cytosolic toxin dropped below the threshold
quantity. Our data further indicated the cytosolic toxin can be removed by proteasomal activity.
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Table 3. Glycerol prevents further CTA1 translocation and proteasomal activity removes CTA1
from the cytosol.
Chase condition

ng cytosolic CTA1

CTA1 molecules per cell

cAMP response

0.02 ± 0.005

2,103

-

No treatment

0.66 ± 0.19

93,249

+

+ glycerol after 30 min

0.01 ± 0.006

1,683

-

+ glycerol & ALLN after 30 min

0.056 ± 0.03

7,899

+

30 min
No treatment
120 min
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Figure 10. Glycerol prevents further translocation of CTA1 to the cytosol.
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Figure 11. Glycerol prevents cAMP activation.
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We have now established that a threshold quantity of cytosolic toxin must be reached in
order to elicit a cytopathic effect, and CTA1 must be continually delivered to the cytosol in order
to overcome the constant proteasome-mediated clearance of cytosolic toxin. We also have
established the use of multiple drugs to block this delivery of CTA1 to the cytosol. We next
looked into the possibility of recovery with the idea that post-exposure inhibition of toxin
translocation could reverse the effects of intoxication. If a there is a threshold of CTA1 required
to be present in the cytosol of a cell, there is the possibility of blocking translocation, after CTA1
has entered the cytosol and cAMP response to the intoxication has begun, allowing the cell to
degrade the toxin already present and reverse the response initiated by that quantity of toxin.
Table 4 shows data of a lengthier intoxication with and without treatment of glycerol after 1 hour
of intoxication for an additional 2, 4, or 8 hours at 37°C. The quantity of cytosolic CTA1 and
the levels of intracellular cAMP were recorded at each chase interval. Glycerol-treated cells
contained less cytosolic CTA1 at 3, 5, and 9 hours of chase than untreated cells at the time of
drug treatment.
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Table 4. A post-exposure block of toxin translocation results in the time-dependent clearance of
CTA1 from the cytosol.
Chase condition

ng cytosolic CTA1

CTA1 molecules per cell

1 hr

0.05 ± 0.01

7,164

3 hr

0.39 ± 0.17

60,110

5 hr

7.6 ± 3.8

1,169,661

9 hr

102 ± 27

15,712,156

3 hr

0.02 ± 0.007

3,264

5 hr

0.04 ± 0.02

6,602

9 hr

0.06 ± 0.03

9,390

No treatment

+ glycerol after 1 hr
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CHAPTER FOUR: DISCUSSION
We have shown a correlation between cytosolic CTA1 quantity and toxin activity through
breakthrough research techniques. The ability to determine the quantity of cytosolic CTA1 with
the use of SPR and cytosolic CTA1 activity through the use of direct cAMP measurements
makes this research pivotal to the future development of toxin research and post-exposure toxin
therapeutics. We have for the first time directly calculated toxin levels in the cytosol of a host
cell and the cellular response it elicits. This data supports the idea that there is a minimal quantity
of CTA1 that must persist in the cytosol to induce the cAMP response and resulting toxicity to
the cell. We have determined the threshold quantity of cytosolic CTA1 is required to elicit a
toxic effect is.05ng. A kinetic requirement of greater than 30 minutes of toxin exposure also
appears necessary for active intoxication.
CTA1 must be continually delivered from the cell surface to the cytosol in order to
overcome the constant proteasome-mediated clearance of cytosolic toxin, and we believe this is
direct evidence of the presence of this threshold requirement. A threshold model is contrary to
the current idea that only one molecule of cytosolic toxin is required to affect host cells
irreversibly. Using various drug treatments that block CTA1 translocation to the cytosol, we
have documented a decrease in the amount of CTA1 that was in the cytosol prior to drug
treatment due to degradation of CTA1 by the proteasome. Thus, proteasomal activity could
lower the quantity of cytosolic CTA1 below the threshold when translocation to the cytosol is
blocked even after toxin exposure. By blocking ER to cytosol translocation the cell is able to
reduce toxin levels in the cytosol below the required threshold quantity. Treatment with glycerol
at 1 hour post exposure and carried out to chase intervals outward to 9 hours support this
possibility.
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We have also shown decreased toxin activity with drug treatment that we attribute to
regulatory factors native to the cell reducing and reversing toxin activity. This would refute the
idea that only one molecule of cytosolic toxin is sufficient to generate a toxic effect. ADPribosylation of G proteins as well as cAMP levels are regulated events that can be reversed by
cellular mechanisms. This implies it is possible to reverse these effects of intoxication and fully
recover from intoxication. When CTA1 passage from the ER to the cytosol was blocked after
exposure to the toxin, proteasomal activity lowered the amount of toxin already in the cytosol
below the threshold quantity. This post-exposure block of toxin translocation will both allow the
intoxicated cell to clear the cytosol of toxin and reverse the effects of intoxication.
Glycerol does not represent an administrable drug but is used for proof-of-principal.
However, PBA is an FDA-approved drug used for disorders involving the urea cycle. GA is
being used in clinical trials against cancer. PBA and GA block by different mechanisms. Due to
the fact that they act on different sites of intoxication, we can use them together for an additive
effect of preventing intoxication. In future work we will establish the therapeutic utility of these
drugs using Caco-2 cells, a polarized intestinal epithelial cell line. We also will be adding much
longer chase times, carried out to 48 hours, in efforts to monitor intoxication and the reversal of
intoxication over the life-span of an intestinal epithelial cell in vivo. We will also establish the
minimal effective dose of these drugs as they are a novel use for both PBA and GA. CTA1
translocation has not been previously targeted as a method for intoxication treatment or reversal,
but our results indicate it to be a promising target.
We believe with this data we have shown cholera is a reversible process that could be
treated after the onset of symptoms. The research of cholera specific entry will bring more light
to research of AB toxins as a whole. There are many AB toxins such as diphtheria, pertussis, and
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shiga toxin that cause a variety of life threatening diseases and have similarities amongst their
cellular mechanisms. CT is secreted into the intestinal lumen, but moves in a retrograde manner
through the vesicles of the cell to act within the cytosol of host cells, a common trend among AB
toxins., Ricin, shiga toxin, pertussis toxin, and Escherichia coli type I heat-labile enterotoxin also
move in this retrograde fashion from the cell surface and exploit ERAD to gain entry to the
cytosol where there A subunits are functional. This makes research on cholera especially
significant and relevant as a model for other AB toxin research and treatment. The threshold and
reversible nature of CT intoxication may be present for other toxins. Research of cholera specific
entry will bring more light to research of related toxin-mediated diseases as a whole.
CTA hijacks the normal cellular mechanism of ERAD, a quality control system in place
to rid the cell of misfolded proteins. It is understood that using these drugs to inhibit ERAD in
order to prevent CTA1’s export to the cytosol may also interfere with the cell’s necessity to
export misfolded proteins for degradation. This may lead to cell toxicity directly. However
Hsp90 and PBA are already administered therapeutics with low toxicity during the required short
term treatment. Both drugs are also effective at relatively lower concentrations then what is
normally used. The localized delivery of therapeutics directly to the intestine that does not
require a systemic administration also aids in reducing side effects. In future work we hope to
see over the longer time course of drug treatment, once cells have shown recovery from
intoxication, no adverse side effects. The cells may be able to cope with certain steps in the
ERAD system being suspended for certain periods of time. These experiments will be carried out
once again in CaCo2 cells, a polarized epithelial cell line, to show the clinical relevance in a
more cholera intoxication-specific cell type.
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These experiments have stringently established a method for cholera toxin research. We
have for the first time determined and precisely quantified the threshold quantity of cytosolic
toxin that must be reached in order to elicit a cytopathic effect. Furthermore, the cytosolic pool
of toxin must be maintained at this level for active intoxication. With this data we intend to
further our understanding of cholera toxin’s mechanism within the human body and be able to
continue with more educated drug discovery concerning how cholera intoxication can be treated
and reversed once a person is intoxicated. Our research suggests it is possible to both treat and
reverse the effects of cholera even after the onset of disease, which opens the door to new
therapeutic strategies.
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